BSW Wealth Partners Acquires 17,274 Shares of Pfizer Inc. (NYSE:PFE)

BSW Wealth Partners lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 32.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 70,209 shares of the biopharmaceutical company’s stock after purchasing an additional 17,274 shares during the period. BSW Wealth Partners’ holdings in Pfizer were worth $1,779,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PFE. Elevated Capital Advisors LLC lifted its stake in Pfizer by 3.7% in the first quarter. Elevated Capital Advisors LLC now owns 24,421 shares of the biopharmaceutical company’s stock valued at $619,000 after buying an additional 869 shares during the period. Gold Investment Management Ltd. raised its position in shares of Pfizer by 4.9% during the first quarter. Gold Investment Management Ltd. now owns 52,801 shares of the biopharmaceutical company’s stock worth $1,338,000 after purchasing an additional 2,488 shares during the period. QSM Asset Management Ltd raised its position in Pfizer by 51.7% in the 1st quarter. QSM Asset Management Ltd now owns 404,802 shares of the biopharmaceutical company’s stock valued at $10,118,000 after buying an additional 138,000 shares during the last quarter. Money Concepts Capital Corp raised its position in Pfizer by 0.3% in the 1st quarter. Money Concepts Capital Corp now owns 208,604 shares of the biopharmaceutical company’s stock valued at $5,286,000 after buying an additional 533 shares during the last quarter. Finally, Achmea Investment Management B.V. raised its position in Pfizer by 194.2% in the 1st quarter. Achmea Investment Management B.V. now owns 311,902 shares of the biopharmaceutical company’s stock valued at $7,904,000 after buying an additional 205,886 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Pfizer stock opened at $24.20 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The business has a fifty day moving average price of $23.46 and a 200-day moving average price of $24.85. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market capitalization of $137.56 billion, a P/E ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the company earned $0.82 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.